PYGM and FADS2

Data Source:
BioGRID (affinity chromatography technology)

		PYGM	FADS2
Description		glycogen phosphorylase, muscle associated	fatty acid desaturase 2
Image			No pdb structure
GO Annotations	Cellular Component	Cytoplasm Cytosol Extracellular Exosome	Endoplasmic Reticulum Membrane Integral Component Of Plasma Membrane Membrane
	Molecular Function	Nucleotide Binding Protein Binding Glycogen Phosphorylase Activity Pyridoxal Phosphate Binding Linear Malto-oligosaccharide Phosphorylase Activity SHG Alpha-glucan Phosphorylase Activity	Stearoyl-CoA 9-desaturase Activity Linoleoyl-CoA Desaturase Activity
	Biological Process	Glycogen Metabolic Process Glycogen Catabolic Process	Unsaturated Fatty Acid Biosynthetic Process Alpha-linolenic Acid Metabolic Process Linoleic Acid Metabolic Process
Pathways		Glycogen breakdown (glycogenolysis) Glycogen breakdown (glycogenolysis)	Linoleic acid (LA) metabolism alpha-linolenic acid (ALA) metabolism alpha-linolenic acid (ALA) metabolism
Drugs		Pyridoxal phosphate Beta-D-Glucopyranose Spirohydantoin (5S,7R,8S,9S,10R)-3-Amino-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione alpha-D-glucose 6-phosphate N-beta-D-glucopyranosylacetamide Monofluorophosphate ion Beta-D-Glucose 3,8,9,10-tetrahydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Nojirimycine Tetrazole Indirubin-5-sulphonate 2-Deoxy-Glucose-6-Phosphate C-(1-hydrogyl-beta-D-glucopyranosyl) formamide alpha-D-glucopyranosyl-2-carboxylic acid amide alpha-D-glucose-1-phosphate 8,9,10-Trihydroxy-7-hydroxymethyl-2-thioxo-6-oxa-1,3-diaza-spiro[4.5]decan-4-one 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole N-acetyl-N'-beta-D-glucopyranosyl urea 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole CP-320626 (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester 8,9,10-trihydroxy-7-hydroxymethyl-3-methyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Alvocidib 1-deoxy-1-methoxycarbamido-beta-D-glucopyranose N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide 1-Deoxy-1-methoxycarbamido-beta-D-gluco-2-heptulopyranosonamide 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium N(6)-(pyridoxal phosphate)-L-lysine Heptulose-2-Phosphate N-(Benzoylcarbamoyl)-beta-D-glucopyranosylamine Dexfosfoserine 1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide Inosinic Acid 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL ({[(3E)-2'-Oxo-2',7'-dihydro-2,3'-biindol-3(7H)-ylidene]amino}oxy)acetic acid (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol	alpha-Linolenic acid
Diseases		Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
GWAS		Urate levels ( 21768215)	Albumin-globulin ratio ( 29403010) anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Aortic valve stenosis ( 32186652) Apolipoprotein A1 levels ( 32203549) Apolipoprotein B levels ( 32203549) Asthma ( 31959851 32296059 31619474) Asthma (adult onset) ( 31036433) Bipolar disorder ( 28115744 31043756) Bipolar I disorder ( 31043756) Brain morphology (MOSTest) ( 32665545) C-reactive protein levels or LDL-cholesterol levels (pleiotropy) ( 27286809) Change in serum metabolite levels ( 31636271) Change in serum metabolite levels (CMS) ( 31636271) Cholesterol, total ( 24097068 19060911 25961943 20686565) Cholesteryl ester levels ( 31551469) Colorectal cancer ( 24836286) Comprehensive strength and appendicular lean mass ( 22960237) Crohn's disease ( 28067908) Delta-5 desaturase activity response to n3-polyunsaturated fat supplement ( 29246731) Electrocardiogram morphology (amplitude at temporal datapoints) ( 32916098) Eosinophil percentage of white cells ( 32888494) Fatty acid desaturase activity (serum) ( 30453627) Gallstone disease ( 30504769) Glycated hemoglobin levels ( 24647736 28898252) Glycerophospholipid levels ( 26068415) Gondoic acid (20:1n-9) levels ( 28298293) Granulocyte count ( 27863252) Granulocyte percentage of myeloid white cells ( 27863252) HDL cholesterol ( 24097068 19060906 19060911 25961943 20686565) HDL cholesterol levels ( 32203549 28334899 30698716) HDL cholesterol levels in current drinkers ( 30698716) HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Heel bone mineral density ( 28869591) Height ( 31562340) Hematocrit ( 32888494) Hemoglobin A1c levels ( 29403010) Hemoglobin levels ( 32327693) IgA levels ( 28628107) Inflammatory bowel disease ( 23128233) Iron status biomarkers (transferrin levels) ( 25352340) Laryngeal squamous cell carcinoma ( 25194280) LDL cholesterol ( 24097068 19060910 19060911 25961943 20686565) LDL cholesterol levels ( 32203549 28334899 30698716) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x long total sleep time interaction (2df test) ( 31719535) LDL cholesterol levels x short total sleep time interaction (2df test) ( 31719535) Lipid metabolism phenotypes ( 22286219) Liver enzyme levels (alkaline phosphatase) ( 22001757) Low density lipoprotein cholesterol levels ( 32154731) Lung cancer in ever smokers ( 28604730) Lymphocyte percentage of white cells ( 32888494) Lysophosphatidylcholine levels ( 31551469) Lysophosphatidylethanolamine levels ( 31551469) Male-pattern baldness ( 28196072) Mean platelet volume ( 32888494 27863252) Mean reticulocyte volume ( 32888494) Medication use (adrenergics, inhalants) ( 31015401) Medication use (thyroid preparations) ( 31015401) Metabolic syndrome ( 20694148 31589552) Metabolite levels ( 23823483 23378610 22916037) Metabolite levels (lipid measures) ( 27005778) Metabolite risk score for predicting weight gain ( 31560688) Monocyte percentage of white cells ( 32888494) Moyamoya disease ( 29273593) Myeloid white cell count ( 27863252) Neutrophil count ( 27863252) Neutrophil percentage of white cells ( 32888494) Non-albumin protein levels ( 29403010) Oleic acid (18:1n-9) levels ( 28298293 23362303) P wave duration ( 24850809) Palmitoleic acid (16:1n-7) levels ( 28298293 23362303) Phosphatidylcholine levels ( 31551469) Phosphatidylcholine-ether levels ( 31551469) Phosphatidylethanolamine levels ( 31551469) Phosphatidylethanolamine-ether levels ( 31551469) Phosphatidylinositol levels ( 31551469) Phospholipid levels (plasma) ( 22359512) Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid) ( 21829377) Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid) ( 21829377) Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid) ( 21829377) Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid) ( 24823311) Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid) ( 24823311) Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid) ( 24823311) Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid) ( 24823311) Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid) ( 24823311) Platelet count ( 29403010 32888494) Platelet distribution width ( 32888494) Plateletcrit ( 32888494 27863252) PR interval ( 32439900) Pulse pressure ( 30578418) QRS duration ( 27659466) QT interval ( 24952745 29874175) Red blood cell fatty acid levels ( 25500335) Red cell distribution width ( 32888494 27863252) Refractive error ( 32231278) Response to statin therapy ( 20339536) Resting heart rate ( 29769521 27798624) Rheumatoid arthritis ( 30423114 24390342) Serum metabolite concentrations in chronic kidney disease ( 29545352) Serum metabolite levels ( 31636271 23093944) Serum metabolite levels (CMS) ( 31636271) Serum metabolite ratios in chronic kidney disease ( 29545352) Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome ( 31991592) Sphingolipid levels ( 26068415 22359512) Sphingomyelin levels ( 31551469) Stearic acid (18:0) levels ( 23362303) Sum basophil neutrophil counts ( 27863252) Sum neutrophil eosinophil counts ( 27863252) Total cholesterol levels ( 28334899 29403010) Triacylglyceride levels ( 31551469) Triacylglycerol 56:6 levels ( 31560688) Triglyceride levels ( 32203549 28334899 32154731 30698716) Triglyceride levels in current drinkers ( 30698716) Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Triglycerides ( 24097068 19060906 25961943 20686565) Urate levels ( 31578528) Vaccenic acid (18:1n-7) levels ( 28298293) Vitiligo ( 27723757)
Interacting Genes		29 interacting genes: AGTPBP1 ARID1B CDC42BPB CLASP2 DNM2 FAM110A IGBP1 INTS4 LMNA NIPSNAP2 NTAQ1 PDE4DIP POMP PPP1CA PPP1R3B PPP2CA PRKAB2 PYGB PYGL S100A1 SGCG SRP72 TOP1 TRAPPC2 TRIM54 TRIM55 TRIM63 TTN WWP1	6 interacting genes: ATXN1L KRT31 KRT40 NBPF19 NOTCH2NLA ZNF655
Entrez ID		5837	9415
HPRD ID		01986	05854
Ensembl ID		ENSG00000068976	ENSG00000134824
Uniprot IDs		P11217	O95864
PDB IDs		1Z8D
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?